臨床婦人科産科76巻3号

2022年04月発行

今月の臨床 がん遺伝子検査に基づく婦人科がん治療―最前線のレジメン選択法を理解する

治療薬

PARP-trapping作用からみたPARP阻害薬の感受性因子と抵抗性因子

著者： 村井純子¹

所属機関： ¹慶應義塾大学先端生命科学研究所

ページ範囲：P.354 - P.360

文献概要

●PARP-trappingはPARP阻害薬の主要な作用機序であり，可逆的という点で従来のDNA障害型抗がん薬と異なる．

●PARP阻害薬感受性，抵抗性にはBRCA変異に加えて，さまざまなDNA修復因子，複製ストレス応答因子，複製フォーク保護因子ほかが関与する．

●PARP-trappingにより複製ストレスが惹起されるとSLFN11が感受性因子，ATRが耐性因子として作用する．

参考文献

1）Bryant HE, et al : Specific killing of BRCA2-deficient tumours with inhibitors of poly（ADP-ribose）polymerase. Nature 434 : 913-917, 2005

2）Farmer H, et al : Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 : 917-921, 2005

3）Murai J, et al : Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72 : 5588-5599, 2012

4）Murai J, et al : Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13 : 433-443, 2014

5）Murai J, et al : PARP trapping beyond homologous recombination and platinum sensitivity in cancers. Annu Rev Cancer Biol 3 : 131-150, 2019

6）Murai J : Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int J Clin Oncol 22 : 619-628, 2017

7）Saha LK, et al : Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes. Nucleic Acids Res 49 : 10493-10506, 2021

8）Blessing C, et al : The oncogenic helicase ALC1 regulates PARP inhibitor potency by trapping PARP2 at DNA breaks. Mol Cell 80 : 862-875.e6, 2020

9）Demin AA, et al : XRCC1 prevents toxic PARP1 trapping during DNA base excision repair. Mol Cell 81 : 3018-3030.e5, 2021

10）Sun K, et al : A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 9 : 37080-37096, 2018

11）Murai J, et al : Rationale for poly（ADP-ribose）polymerase（PARP）inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349 : 408-416, 2014

12）Fugger K, et al : Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science 372 : 156-165, 2021

13）Murai J, et al : Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7 : 76534-76550, 2016

14）Murai J, et al : Schlafen 11（SLFN11）, a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther 201 : 94-102, 2019

15）Takashima T, et al : Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers. Br J Cancer 125 : 65-77, 2021

16）Lok BH, et al : PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 23 : 523-535, 2017

17）Sakai W, et al : Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 : 1116-1120, 2008

18）Lheureux S, et al : EVOLVE : A multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin Cancer Res 26 : 4206-4215, 2020

19）Tang SW, et al : Overcoming resistance to DNA-targeted agents by epigenetic activation of schlafen 11（SLFN11）expression with class i histone deacetylase inhibitors. Clin Cancer Res 24 : 1944-1953, 2018